Cargando…
Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
Hepatocellular cancer is the sixth most frequently diagnosed malignant disease worldwide, and was responsible for tens of millions of deaths in 2020; however, treatment options for patients with advanced hepatocellular carcinoma remain limited. Immunotherapy has undergone rapid development over rece...
Autores principales: | He, Yuqing, Lu, Mengyao, Che, Jing, Chu, Qian, Zhang, Peng, Chen, Yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450565/ https://www.ncbi.nlm.nih.gov/pubmed/34552872 http://dx.doi.org/10.3389/fonc.2021.716844 |
Ejemplares similares
-
Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma
por: Peng, Xuenan, et al.
Publicado: (2023) -
Phosphogluconate dehydrogenase is a predictive biomarker for immunotherapy in hepatocellular carcinoma
por: Liu, Tiantian, et al.
Publicado: (2022) -
Hepatocellular Senescence: Immunosurveillance and Future Senescence-Induced Therapy in Hepatocellular Carcinoma
por: Liu, Peng, et al.
Publicado: (2020) -
Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
por: Guo, Zhanjun, et al.
Publicado: (2022) -
Application of Immunotherapy in Hepatocellular Carcinoma
por: Miao, Lele, et al.
Publicado: (2021)